CYP2J deficiency leads to cardiac injury and presents dual regulatory effects on cardiac function in rats.

[1]  Jie Liu,et al.  Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs. , 2022, Life sciences.

[2]  S. Ong,et al.  Evaluation of cardiovascular diseases risk calculators for CVDs prevention and management: scoping review , 2022, BMC Public Health.

[3]  K. Kuwahara.  The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications. , 2021, Pharmacology & therapeutics.

[4]  D. Judge,et al.  International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework , 2021, Circulation. Genomic and precision medicine.

[5]  S. Alzahrani,et al.  Cardiac Injury Biomarkers and the Risk of Death in Patients with COVID-19: A Systematic Review and Meta-Analysis , 2021, Cardiology research and practice.

[6]  V. Garcia,et al.  Unraveling the role of 12- and 20-HETE in cardiac pathophysiology: G-protein coupled receptors, pharmacological inhibitors and transgenic approaches. , 2021, Journal of cardiovascular pharmacology.

[7]  Ang Chen,et al.  Investigation of the content differences of arachidonic acid metabolites in a mouse model of breast cancer by using LC-MS/MS. , 2020, Journal of pharmaceutical and biomedical analysis.

[8]  Mingyao Liu,et al.  Generation and Characterization of Cytochrome P450 2J3/10 CRISPR/Cas9 Knockout Rat Model , 2020, Drug Metabolism and Disposition.

[9]  J. Seubert,et al.  Mitochondrial Dysfunction and Inflammaging in Heart Failure: Novel Roles of CYP-Derived Epoxylipids , 2020, Cells.

[10]  L. Lund,et al.  Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[11]  J. Falck,et al.  Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats , 2019, Clinical science.

[12]  N. Sotoodehnia,et al.  Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes , 2018, International journal of molecular sciences.

[13]  Chaofeng Sun,et al.  Dysfunctional Nav1.5 channels due to SCN5A mutations , 2018, Experimental biology and medicine.

[14]  M. Arad,et al.  CYP-450 Epoxygenase Derived Epoxyeicosatrienoic Acid Contribute To Reversal of Heart Failure in Obesity-Induced Diabetic Cardiomyopathy via PGC-1 α Activation , 2018, Cardiovascular pharmacology: open access.

[15]  E. Braunwald,et al.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. , 2017, Circulation research.

[16]  Benqiang Deng,et al.  Association of CYP2J2 gene polymorphisms with ischemic stroke and stroke subtypes in Chinese population , 2017, Medicine.

[17]  J. Falck,et al.  Novel Roles of Epoxyeicosanoids in Regulating Cardiac Mitochondria , 2016, PloS one.

[18]  Bei Wang,et al.  CYP2J2 and its metabolites (epoxyeicosatrienoic acids) attenuate cardiac hypertrophy by activating AMPKα2 and enhancing nuclear translocation of Akt1 , 2016, Aging cell.

[19]  Wanjun Liu,et al.  CYP2J2 Overexpression Increases EETs and Protects Against HFD-Induced Atherosclerosis in ApoE−/− Mice , 2016, Journal of cardiovascular pharmacology.

[20]  J. Marín-García,et al.  Mitochondrial dynamics and cell death in heart failure , 2016, Heart Failure Reviews.

[21]  Jian-Ping Jin,et al.  TNNI1, TNNI2 and TNNI3: Evolution, regulation, and protein structure-function relationships. , 2016, Gene.

[22]  Shasha Zhang,et al.  Epoxyeicosatrienoic Acids Regulate Macrophage Polarization and Prevent LPS‐Induced Cardiac Dysfunction , 2015, Journal of cellular physiology.

[23]  J. Jones,et al.  Activity, Inhibition, and Induction of Cytochrome P450 2J2 in Adult Human Primary Cardiomyocytes , 2013, Drug Metabolism and Disposition.

[24]  Ping Li,et al.  Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance , 2013, Drug metabolism reviews.

[25]  A. El-Kadi,et al.  Cytochrome P450 epoxygenase metabolite, 14,15-EET, protects against isoproterenol-induced cellular hypertrophy in H9c2 rat cell line. , 2013, Vascular pharmacology.

[26]  A. El-Kadi,et al.  Role of cytochrome P450–mediated arachidonic acid metabolites in the pathogenesis of cardiac hypertrophy , 2013, Drug metabolism reviews.

[27]  B. Hammock,et al.  Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. , 2013, Annual review of pharmacology and toxicology.

[28]  Hong-Xia Wang,et al.  Upregulation of cytochrome P450 2J3/11,12-epoxyeicosatrienoic acid inhibits apoptosis in neonatal rat cardiomyocytes by a caspase-dependent pathway. , 2012, Cytokine.

[29]  Johan Auwerx,et al.  PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure , 2009, Current opinion in lipidology.

[30]  T. Chan,et al.  TNF-alpha reduces PGC-1alpha expression through NF-kappaB and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model. , 2009, Cardiovascular research.

[31]  A. Polonikov,et al.  A Common Polymorphism G-50T in Cytochrome P450 2J2 Gene Is Associated with Increased Risk of Essential Hypertension in a Russian Population , 2008, Disease markers.

[32]  T. Lu,et al.  Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms , 2006, The Journal of physiology.

[33]  N. Maeda,et al.  The role of natriuretic peptides in cardioprotection. , 2006, Cardiovascular research.